"We focus on the maximum point of leverage between Signal Capture → Signal Exploit so AIML can deliver measurable gains in quality & speed - at scale"
From noisy inputs to high-quality, labeled, analysis-ready signal — in seconds to minutes.
Device-agnostic: supports 1–12 leads, 10-second to 30-day recordings.
Waveform-aware segmentation — precisely identifying P-wave, QRS, and T-wave boundaries.
Triple outputs: beat-by-beat label matrix · time-series intervals · anomaly detection streams.
Between Signal Capture → Signal Exploit lives the fulcrum of every ECG workflow — where leverage is highest and why input quality dictates every downstream outcome.
Exploit with a clean labelled signal, and everything that follows — classification, triage, and interpretation — becomes faster, clearer, and more reliable.
MaxYield doesn’t filter noise away; it understands it. Our neural networks perform waveform-aware segmentation, pinpointing the onset and offset of the P-wave, the exact QRS duration, and T-wave boundaries—the fundamental building blocks of cardiovascular diagnostics, even in noisy environments.
One Engine — Three Synchronized OutputsMaxYield generates a unified stream of clinical intelligence, structured in three precise layers:
Beat-by-beat label matrix — for classification and triage logic, capturing every P, QRS, and T morphology.
Time-series stream — for beat-level intervals, rhythm trends, and longitudinal analysis.
Event & anomaly table — for detected arrhythmias, signal artifacts, and other irregular events.Together, they deliver analysis-ready ECG data — from noise to insight — in seconds to minutes.
Incumbent clinical tools: Strengthening existing diagnostic workflows across OEM platforms.
CardioYield™: The clinical diagnostic and decision-support engine for care environments.Insight360: The research and wellness platform driving prevention, performance, and longevity analytics.
MaxYield ECG at the CenterThe neural core that powers it all — transforming raw ECG into usable intelligence that fuels clinical precision, research discovery, and human performance.
Proprietary, patented ECG neural networks built to own the chokepoint between signal capture and signal exploit - and co-designed with leading cardiologists and electrophysiologists to power CardioYield™, our clinical diagnostic support platform.
A leadership team blending world-class electrophysiologists, cardiologists, cardio technicians, biomedical engineers, and commercial operators — each proven at scale.
Decades of success turning advanced digital technologies into adoption - leveraging direct access to healthcare leaders, clinical networks, and distribution partners across clinics, research, and consumer wellness markets.
Executive Chairman & CEO, AI/ML Innovations Inc.
"I’ve spent my career building the bridge between innovation and adoption - transforming ideas into technologies that reach the world"
Paul Duffy is a serial entrepreneur, operator, and innovator with over three decades of experience turning advanced technologies into scaled, real-world businesses. Commercializing innovation where technology meets human impact.
He has founded and led multiple successful ventures across AI, neural networks, augmented reality, and digital health - consistently building bridges between cutting-edge R&D and large-scale commercialization.
Paul’s early career saw the launch of eSchool Essentials™ at CCI - the first on-demand learning platform built for Microsoft Office, distributed globally to reduce computer illiteracy.
In 2014, he co-founded ARHT Media Inc. with Paul Anka and René Bharti, where he invented and patented holographic telepresence technology - enabling luminaries such as Professor Stephen Hawking, Warren Buffett, Deepak Chopra, Tony Robbins, and Justin Trudeau to appear live, as holograms, around the world.
He later co-founded NexTech AR Solutions Corp. to help lead the global adoption of augmented reality, scaling immersive content for enterprise and education.
In 2022, Paul expanded MoonShot Inc., his early-stage investment and commercialization firm, to focus on AI, machine learning, neural networks, and spatial computing. MoonShot serves as both investor and operator - rapidly accelerating ventures from lab to market, with a proven ability to navigate regulatory pathways, integrate into enterprise ecosystems, and drive adoption.
Today, as CEO of AI/ML Innovations Inc. (AIML), Paul leads the company’s mission to redefine cardiovascular diagnostics through neuralized ECG intelligence - combining world-class clinical expertise with deep technology and commercialization experience.
As a passionate advocate for humanizing technology, Paul is a dynamic and engaging speaker who inspires audiences to think differently about the role of technology in our lives. He holds a Bachelor of Science in Applied Computer Science from the Toronto Metropolitan University, has multiple alumni awards and is a former member of the Board of Governors for the Michener Institute for Applied Health Science.
Professor of Medicine, Cardiology & Pharmacology, University of Toronto;
Staff Scientist at the Li Ka Shing Knowledge Institute;
Staff Cardiac Electrophysiologist at St. Michael’s Hospital;
Medical Innovation Architect and Head of the Medical Advisory Board, AI/ML Innovations Inc.
"Identifying true P and QRS complexes after noise and artefact are removed would substantially increase the probability that a true critical abnormality is captured (sensitivity), while also limiting false positives - which are often detected by Technicians but are time-consuming, fatiguing, and lead to ‘alarm fatigue‘."
Dr. Dorian received his medical degree from McGill University in Montreal in 1976. He completed training in Internal Medicine, Clinical Pharmacology, and Cardiology at the University of Toronto and completed a Fellowship in Cardiac Electrophysiology at Stanford University. He is a Professor of Medicine in the Division of Cardiology and in the Division of Clinical Pharmacology at the University of Toronto, and a Staff Scientist at the Li Ka Shing Knowledge Institute, and is Staff Cardiac Electrophysiologist at St. Michael’s Hospital.
Dr. Paul Dorian was the Department Director, Division of Cardiology, University of
Toronto (2009-2019), and President of the Canadian Heart Rhythm Society (2013-2014).
He is a recipient of the University of Toronto Department of Medicine Research Award, and the Canadian Cardiovascular Society and Canadian Heart Rhythm Society Achievement Awards.
He established the cardiac electrophysiology Program at St Michael’s Hospital in 1990, and has conducted research studies in ambulatory monitoring and novel applications of wearable devices in cardiac diagnosis and care.
He has served and continues to serve on the steering committees of multiple
multicenter clinical trials in arrhythmia care.
He was the principal investigator of the ALIVE RCT of antiarrhythmic drugs in cardiac arrest, the Family study on predicting and preventing sudden cardiac death, the CIHR funded EpiDOSE Trial, and the Program to reduce sudden death funded by the Canadian Arrhythmia Network.
He has led a basic science research program on the mechanisms of ventricular fibrillation, treatment of experimental cardiac arrest, and the circulatory and electrophysiology of cardio pulmonary resuscitation.
He has also been active in a research program on the establishment of optimum systems of care for patients with atrial fibrillation, including assessment of quality of life in patient reported outcomes. He designed and led the implementation of scales to measure quality of life in AF, including the Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF) score, The AFSS scale, and the AFEQT scale, which are the most used methods for the measurement of quality of life in patients with AF.
He is one of the core participants of the University of Toronto Sports Cardiology
Program which brings together academic researchers, academic and community cardiologists, physiology researchers, students, and patients in the establishment of a clinical and research program in sports cardiology. He has led studies on the incidence and causes of sudden death in competitive sport, and the diagnostic accuracy of the ECG in athlete screening.
He has served on the CCS guidelines/position paper writing panel committee for atrial fibrillation, heart failure, ventricular arrhythmia, and athlete preparticipation screening.
He has published over 580 peer reviewed papers and is Associate Editor of the textbook Electrophysiological Disorders of the Heart.
Chief Product Officer, AI/ML Innovations Inc.
President, Neural Cloud Solutions
Leads the development of advanced neural network systems while scaling AI-enabled revenue operations, driving AIML’s innovation to transform how data and automation shape modern medicine.
Esmat Naikyar brings a unique blend of technical expertise, entrepreneurial vision, and operational leadership to his role as President of Neural Cloud Solutions and Chief Product Officer at AIML. A Chemical Engineering graduate from the University of Alberta, Esmat has extensive experience in research and development and was one of the original founders behind the company’s core technology, guiding it from inception to its current stage of journey.
Beyond leading product development, Esmat now drives revenue operations as AIML scales, implementing modern, AI-enabled strategies to optimize sales and operational efficiency. At the helm of Neural Cloud Solutions, he oversees the design and deployment of advanced neural network systems that, unlock insights from complex healthcare data, and advance the frontier of AI and machine learning in medicine.
Esmat’s dual focus on innovation and scalable growth positions him at the intersection of product, technology, and business strategy, ensuring that AIML not only pioneers cutting-edge AI solutions but also brings them to market efficiently and effectively
Chief Operating Officer
(AI/ML Innovations & Neural Cloud Solutions)
Erik brings more than 20 years of senior leadership experience across healthcare, MedTech, SaaS, and highly regulated clinical environments. He has a proven track record of building high-performing teams, accelerating revenue growth, and operationalizing scalable commercial strategies in complex, cross-border markets.
As National Director at Sun Nuclear Corp., Erik launched and scaled the Canadian direct-sales organization, transitioning from a distributor-based model to a direct enterprise commercial strategy to drive sustained market and revenue growth.
Earlier in his career, Erik was in a senior leadership role at Canadian Orthodontic Partners, where he led acquisitions along with post-merger integration across Canada and the United States.
Erik has also held various commercial and leadership positions at Abbott Medical, St. Jude Medical, Align Technology, and Medtronic, with experience spanning cardiology, diagnostics, enterprise healthcare partnerships, and the delivery of regulated clinical solutions.
Erik holds a Doctor of Chiropractic (DC), Juris Doctor (JD), and MBA in Finance, bringing a unique multidisciplinary combination of clinical insight, legal fluency, and operational discipline that supports AIML’s mission to scale responsibly within complex clinical and regulatory environments.
Platform Strategist – Data Intelligence, AIML Innovations Inc.
Specializes in identifying and financing early-stage innovators shaping the next wave of high-growth industries.
Jakson Inwentash is an accomplished investor and strategic operator with deep expertise in identifying, evaluating, and scaling early-stage disruptive technology companies. As Director and VP Investments at ThreeD Capital Inc., a leading venture capital firm specializing in early-stage investments across high-growth sectors such as AI, biotechnology, fintech, IoT, renewable energy, and blockchain, Jakson has played a key role in sourcing and conducting due diligence on breakthrough ventures that have gone on to achieve significant success and exits.
At ThreeD, Jakson is known for his ability to recognize emerging technologies ahead of the curve, building conviction through rigorous research and hands-on engagement with founders. Beyond capital deployment, he provides strategic advisory and operational support to portfolio companies - helping drive business development, capital markets strategy, and growth execution. His extensive network across investors, founders, and corporate partners enables portfolio companies to access the resources they need to scale rapidly. He also serves as an advisor and board member to several private and publicly listed companies, reflecting his broad impact across the innovation ecosystem.
In addition to his investment leadership, Jakson serves as Platform Strategist, Data Intelligence at AIML Innovations Inc., where he leads the design and commercialization of AIML’s data intelligence initiatives. His mandate centres on developing the infrastructure and strategic partnerships for a platform that aggregates, structures, and licenses anonymized biometric and diagnostic data - powering advanced modelling, predictive analytics, and biomarker discovery. His work bridges health data, AI, and commercialization, creating a foundation for AIML to deliver scalable, compliant, and revenue-generating data services to global partners.
Dev Team Leader and AI Engineer - NeuralCloud Solutions
Pablo Pietropinto is an entrepreneur and AI architect with more than 25 years of experience designing, building, and scaling technology-driven products.
He currently serves as Dev Team Leader and AI Engineer at AI/ML INNOVATIONS and Neural Cloud, where he leads the development of advanced AI platforms, focusing on data processing, automation, and intelligent systems.
Throughout his career, Pablo has collaborated on projects for global brands such as Huawei, Movistar, Nokia, Universal Music, Claro, LG, PepsiCo, Warner Music, and Samsung, bridging technology, business strategy, and product execution.
AIML’s intellectual property and commercialization strategy is guided by Wolf, Greenfield & Sacks, supported by Dan Rudoy, Stephen Rabinowitz, Edmund Walsh, and Christina Licursi.
This advisory team brings deep experience in medical-device IP, licensing, and cross-border transactions, ensuring AIML’s technologies align with standards for partnership, protection, and scalable deployment across global cardiology markets.
Financed hundreds of private and public start up companies. $30 billion raised to date.
Sheldon Inwentash, B.COMM., CPA, CA., LL.D. (HON), is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful small capital investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, disruptive technologies and junior resources with a particular focus on precious metals. The company was launched following his two-decade tenure as CEO at Pinetree Capital Ltd., an investment, financial advisory and merchant banking firm which he also founded.
Sheldon is well-known for his investment strategies, for revolutionizing the resource investment model and for creating significant shareholder value through early investments. In addition to providing opportunities to investors, he helps the companies in which he invests by providing counsel and guidance to C-suite leaders and, often, by assuming a formal role in company governance as a board member.
Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth. In part, the Doctorate recognizes his $15 million endowment to the university’s social work faculty in tribute to his wife, Lynn Factor, who is deeply committed to social work and is an advocate for children’s welfare. In 2007, he was also named an Ontario finalist for the Ernst & Young entrepreneur-of-the-year award.
Sheldon began his career as an oil and gas analyst for a life insurance firm, and was involved in several biotechnology startups.
When not working, Sheldon, who has great appreciation for contemporary art, is an avid collector.
Financed hundreds of private and public start up companies; Investments fair value reached ~ $800 Million; Firm commanded a market cap north of $1 Billion; Revolutionized the resource investment model.
Successful Unicorn Exits include:
Chief Medical Officer, AIML;
Cardiologist and formerly Director of the Coronary Care Unit, St. Paul's Hospital Heart Centre / Center for Heart Lung Innovation;
Clinical Associate Professor, Division of Cardiology, University of British Columbia
"The Neural Cloud and their AI technology are revolutionizing the way Holter Monitor data is recorded and processed. The signal isolation capabilities are greatly beneficial across all workflows, from technicians to patients."
Dr. Alan Rabinowitz is a cardiologist and Clinical Associate Professor at St Paul's Hospital University of British Columbia, with training from the University of Cape Town and the University of Toronto, and interventional cardiology training at St. Paul’s Hospital, Vancouver. He previously served as Director of the Cardiac Intensive Care Unit at St. Paul’s and has been actively involved in various positions of healthcare leadership in quaternary health institutions, as well as actively involved in service delivery and innovation in underserved rural and remote communities.
Dr. Rabinowitz’s work spans data-driven healthcare, AI in cardiology, and computational biology. He serves on the Canadian Cardiovascular Society AI Advisory Committee, was an advisor to the Royal College of Physicians and Surgeons of Canada, and contributes to health data trust initiatives. He is also engaged in global entrepreneurial efforts to leverage exponential technologies for innovation in healthcare, precision medicine, and collaborative public-private health initiatives.
Professor of Medicine and Physiology, University of Toronto;
Cardiologist and Scientist, St. Michael’s Hospital
Dr. Kim Connelly is a clinician‑scientist recognized for translational research in diabetic cardiomyopathy, advanced cardiac imaging, and regenerative therapies. He directs the Cardio‑Metabolic Research Program at St. Michael’s, where his lab integrates machine‑learning biomarkers with MRI and echo phenotyping. Dr. Connelly has secured >$15 million in competitive funding and has been a key investigator on cell‑based therapy trials for heart failure. His expertise in imaging‑defined endpoints complements MaxYield’s roadmap toward AI‑image data fusion.
Medical Director, Electrodiagnostics Program;
Clinical Associate Professor, Division of Cardiology, University of British Columbia;
St. Paul’s Hospital Heart Centre, Vancouver, BC
"Its superior artifact filtering drastically reduces noise, producing clinically acceptable tracings that enhance the speed and accuracy of Holter analysis."
Dr. Brett Heilbron completed his undergraduate degree at the University of Cape Town (South Africa), and then practiced as a rural family physician in Newfoundland and Manitoba for 4 years. He completed Internal Medicine and Cardiology training at the University of British Columbia in 1995. He has Level 3 Certification in Cardiac Computed Tomography and is a Diplomate of the Certification Board in Cardiac Computed Tomography and a Fellow of the Society of Cardiovascular Computed Tomography.
He has been based at St. Paul’s Hospital since 1997, where he has a clinical practice and works in the Cardiac Catheterization Laboratory. He is Medical Director of the Electrodiagnostics program at St. Paul’s Hospital and Mount St. Joseph’s Hospital, and a Clinical Associate Professor at the University of British Columbia. He is the Cardiology Consultant for Lifelabs British Columbia.
Clinical Professor, University of British Columbia;
Director, Heart Rhythm Services, St. Paul’s Hospital
"Neural Cloud's groundbreaking algorithm in ECG monitoring analysis delivers a level of precision that rivals human expert interpretation and signifies a new era in cardiac diagnostics."
Dr. Marc Deyell is a leading electrophysiologist and clinical researcher whose work spans ventricular‑tachycardia ablation, inherited arrhythmic syndromes, and signal‑processing innovations. As Director of EP at UBC, he supervises a multi‑disciplinary team conducting first‑in‑human trials of AI‑driven ECG analytics—research that underpins MaxYield’s validation datasets.
Independent Director
With a PhD in Audiology & Biomedical Engineering, Dr. Dundas is a recognized innovator in audiological and medical device technology with over two decades of R&D leadership
Dr. Dundas brings over two decades of leadership in technology and research, currently serving as Chief Technology Officer at Earlens Corporation, where he leads research and development efforts across various teams, including research, audiology, marketing, and clinical. Prior to Earlens, Dr. Dundas served as President and CTO of Soundhawk Corporation and Director of Audiology at UCSF Medical Center. His background also includes research at Starkey Hearing Technologies, where he contributed to the development of groundbreaking audiological technologies.
Dr. Dundas holds a PhD in Audiology & Biomedical Engineering from Vanderbilt University, a Master of Arts from The University of Akron in Audiology, and a BSc from McMaster University. In addition, Dr. Dundas is a fellow of the American Academy of Audiology.
Independent Director
As President of the Ontario PC Party and Principal at Upstream Strategy Group, Michael merges political insight with business innovation to help organizations scale within regulated markets.
Mr. Diamond is a Principal of Upstream Strategy Group, a respected public affairs and strategic communications firm. He also serves as the President of the Ontario Progressive Conservative Party and is widely regarded as one of Canada’s most influential voices in political strategy, regulatory affairs, and stakeholder engagement.
In addition to his deep expertise in public policy, Mr. Diamond brings a proven ability to build partnerships, drive business development, and align innovation with government priorities. His strategic lens and real-world experience at the intersection of politics, business, and innovation will directly support AIML’s efforts to scale its AI-powered health technologies across regulated markets.
Independent Director
A capital markets professional with deep experience in financing, Jared has guided numerous early-stage innovators through strategic growth and capital raising.
Mr. Adelstein brings almost a decade of experience in investment banking and capital markets, having worked with several boutique firms in Toronto. His career has been dedicated to advising innovative, high-growth early-stage companies, both in capital markets and operational capacities. He possesses a robust expertise in forecasting and budgeting, operational planning, and capital raising.
AIML’s 2025 Shareholder Update from CEO & Executive Chairman, Paul Duffy, outlining key milestones from 2025 - including Product Development, Commercial Traction, and Regulatory Progress - along with the roadmap for 2026. The livestream concludes with a Q&A with the live audience.
Visit page